Cargando…

Efficacy and tolerability of paroxetine in adults with social anxiety disorder: A meta-analysis of randomized controlled trials

OBJECTIVE: The present study aimed to estimate the comprehensive efficacy and tolerability of paroxetine in adult patients with social anxiety disorder (SAD). METHODS: We conducted a comprehensive literature review of the PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xinyuan, Hou, Yanbo, Su, Yingying, Liu, Hongping, Zhang, Beilin, Fang, Shaokuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220791/
https://www.ncbi.nlm.nih.gov/pubmed/32243377
http://dx.doi.org/10.1097/MD.0000000000019573
_version_ 1783533243436367872
author Li, Xinyuan
Hou, Yanbo
Su, Yingying
Liu, Hongping
Zhang, Beilin
Fang, Shaokuan
author_facet Li, Xinyuan
Hou, Yanbo
Su, Yingying
Liu, Hongping
Zhang, Beilin
Fang, Shaokuan
author_sort Li, Xinyuan
collection PubMed
description OBJECTIVE: The present study aimed to estimate the comprehensive efficacy and tolerability of paroxetine in adult patients with social anxiety disorder (SAD). METHODS: We conducted a comprehensive literature review of the PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, and ClinicalTrials databases for eligible randomized controlled trials (RCTs). The efficacy outcome was the mean change of different kinds of scale scores as well as response and remission rates. The secondary outcome was tolerability, defined as the discontinuation rate and the incidence of adverse events (AEs). RESULTS: Our meta-analysis included 13 RCTs. Mean changes in the Liebowitz Social Anxiety Scale (LSAS) total score, fear and avoidance subscale of LSAS scores were all significantly greater in patients with SAD that received paroxetine compared to those received placebo (total: MD = 13.46, 95%CI 10.59–16.32, P < .00001; fear: MD = 6.76, 95%CI 4.89–8.62, P < .00001; avoidance: MD = 6.54, 95%CI 4.63–8.45, P < .00001). Response and remission rates were both significantly greater in patients with SAD that received paroxetine compared to those received placebo (response: OR = 3.02, 95%CI 2.30–3.97, P < .00001; remission: OR = 3.14, 95%CI 2.25–4.39, P < .00001). There was no significant difference in discontinuation rate due to any reason between two groups (OR = 1.06, 95%CI 0.81–1.39, P = .65). Discontinuation rate due to AEs was higher in paroxetine than placebo group (OR = 3.41, 95%CI 2.45–4.72, P < .00001) whereas the rate due to lack of efficacy was higher in placebo as compared with paroxetine group (OR = 0.14, 95%CI 0.09–0.22, P < .00001). The incidence of any AE was significantly increased in patients that received paroxetine (OR = 1.83, 95%CI 1.43–2.35, P < .00001). CONCLUSION: Paroxetine was an effective and well-tolerated treatment option for adult patients with SAD.
format Online
Article
Text
id pubmed-7220791
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-72207912020-06-15 Efficacy and tolerability of paroxetine in adults with social anxiety disorder: A meta-analysis of randomized controlled trials Li, Xinyuan Hou, Yanbo Su, Yingying Liu, Hongping Zhang, Beilin Fang, Shaokuan Medicine (Baltimore) 6500 OBJECTIVE: The present study aimed to estimate the comprehensive efficacy and tolerability of paroxetine in adult patients with social anxiety disorder (SAD). METHODS: We conducted a comprehensive literature review of the PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, and ClinicalTrials databases for eligible randomized controlled trials (RCTs). The efficacy outcome was the mean change of different kinds of scale scores as well as response and remission rates. The secondary outcome was tolerability, defined as the discontinuation rate and the incidence of adverse events (AEs). RESULTS: Our meta-analysis included 13 RCTs. Mean changes in the Liebowitz Social Anxiety Scale (LSAS) total score, fear and avoidance subscale of LSAS scores were all significantly greater in patients with SAD that received paroxetine compared to those received placebo (total: MD = 13.46, 95%CI 10.59–16.32, P < .00001; fear: MD = 6.76, 95%CI 4.89–8.62, P < .00001; avoidance: MD = 6.54, 95%CI 4.63–8.45, P < .00001). Response and remission rates were both significantly greater in patients with SAD that received paroxetine compared to those received placebo (response: OR = 3.02, 95%CI 2.30–3.97, P < .00001; remission: OR = 3.14, 95%CI 2.25–4.39, P < .00001). There was no significant difference in discontinuation rate due to any reason between two groups (OR = 1.06, 95%CI 0.81–1.39, P = .65). Discontinuation rate due to AEs was higher in paroxetine than placebo group (OR = 3.41, 95%CI 2.45–4.72, P < .00001) whereas the rate due to lack of efficacy was higher in placebo as compared with paroxetine group (OR = 0.14, 95%CI 0.09–0.22, P < .00001). The incidence of any AE was significantly increased in patients that received paroxetine (OR = 1.83, 95%CI 1.43–2.35, P < .00001). CONCLUSION: Paroxetine was an effective and well-tolerated treatment option for adult patients with SAD. Wolters Kluwer Health 2020-04-03 /pmc/articles/PMC7220791/ /pubmed/32243377 http://dx.doi.org/10.1097/MD.0000000000019573 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle 6500
Li, Xinyuan
Hou, Yanbo
Su, Yingying
Liu, Hongping
Zhang, Beilin
Fang, Shaokuan
Efficacy and tolerability of paroxetine in adults with social anxiety disorder: A meta-analysis of randomized controlled trials
title Efficacy and tolerability of paroxetine in adults with social anxiety disorder: A meta-analysis of randomized controlled trials
title_full Efficacy and tolerability of paroxetine in adults with social anxiety disorder: A meta-analysis of randomized controlled trials
title_fullStr Efficacy and tolerability of paroxetine in adults with social anxiety disorder: A meta-analysis of randomized controlled trials
title_full_unstemmed Efficacy and tolerability of paroxetine in adults with social anxiety disorder: A meta-analysis of randomized controlled trials
title_short Efficacy and tolerability of paroxetine in adults with social anxiety disorder: A meta-analysis of randomized controlled trials
title_sort efficacy and tolerability of paroxetine in adults with social anxiety disorder: a meta-analysis of randomized controlled trials
topic 6500
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220791/
https://www.ncbi.nlm.nih.gov/pubmed/32243377
http://dx.doi.org/10.1097/MD.0000000000019573
work_keys_str_mv AT lixinyuan efficacyandtolerabilityofparoxetineinadultswithsocialanxietydisorderametaanalysisofrandomizedcontrolledtrials
AT houyanbo efficacyandtolerabilityofparoxetineinadultswithsocialanxietydisorderametaanalysisofrandomizedcontrolledtrials
AT suyingying efficacyandtolerabilityofparoxetineinadultswithsocialanxietydisorderametaanalysisofrandomizedcontrolledtrials
AT liuhongping efficacyandtolerabilityofparoxetineinadultswithsocialanxietydisorderametaanalysisofrandomizedcontrolledtrials
AT zhangbeilin efficacyandtolerabilityofparoxetineinadultswithsocialanxietydisorderametaanalysisofrandomizedcontrolledtrials
AT fangshaokuan efficacyandtolerabilityofparoxetineinadultswithsocialanxietydisorderametaanalysisofrandomizedcontrolledtrials